The size of the global cancer monoclonal antibodies market is forecasted to worth USD 70.6 billion by 2025 from USD 41.3 billion in 2020, registering a CAGR of 11.31% between 2020 to 2025.
Cancer is a severe disease-causing million of death worldwide every year. Cancer starts from a single cell and genetically transforms a normal cell into a tumor cell and is gradually spread to other cells. With the dramatic increase in the number of people affected by cancer, many pharmaceutical players started to invest in monoclonal antibodies. While the drugs are used to treat cancer, drugs like chemotherapy agents have adverse side effects as they affect the normal cells as well, along with cancerous cells. It prompted the increased usage of Monoclonal Antibodies for the treatment of cancer.
Monoclonal Antibodies (mAbs) are mono-specific antibody bodies comprising identical immune cells that are clones of a single parent cell and directed to specific cellular targets. Thus, Monoclonal Antibodies are highly customizable due to their particular nature and can play a crucial role in eliminating cancerous cells while sparing the normal cells during the cancer treatment. The monoclonal antibodies are proved to be more effective than chemotherapies and drugs for cancer treatment.
Monoclonal Antibodies could offer less toxic and efficient therapeutic alternatives to the patients that have been emerging in recent years. Monoclonal Antibodies are used to treat a wide array of diseases related to autoimmune, inflammatory, and especially cancer.
MARKET DRIVERS:
The dramatic increase in the number of cancer patients has led many pharmaceutical players to invest in the monoclonal antibodies market. Increasing investment in research and development of genomic studies, technological advancements in genetic sequencing and target gene selection, a specificity of monoclonal antibodies to target only the cancer cells with no side effects are some of the driving forces of the market. The increased prevalence of cancer is the key driver for the monoclonal antibodies market. It is expected to grow lucratively in the next five years with the presence of healthy products in the pipeline.
MARKET RESTRAINTS:
However, there are few restraints for the market's growth, like high development cost being the major one. And also, stringent regulatory guidelines, long durations required for the research and development of antibodies, more extended periods of clinical trials are some of the hurdles faced by the global cancer monoclonal antibodies market.
REPORT COVERAGE:
|
REPORT METRIC |
DETAILS |
|
Market Size Available |
2019 to 2025 |
|
Base Year |
2019 |
|
Forecast Period |
2020 to 2025 |
|
Segments Covered |
By Application, Type, Conjugate Cancer Therapies and Region |
|
Various Analyses Covered |
Global, Regional & Country Level Analysis, Segment-Level Analysis, DROC, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities |
|
Regions Covered |
North America, Europe, APAC, Latin America, Middle East & Africa |
|
Market Leaders Profiled |
Amgen, Genmab, GlaxoSmithKline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals. |
This research report on the global cancer monoclonal antibodies market has been segmented and sub-segmented based on application, type, conjugate cancer therapies, and region.
Cancer Monoclonal Antibodies Market - By Application:
Based on the application, the Breast Cancer segment is expected to grow with an outstanding share in the Global Cancer Monoclonal Antibodies Market over the forecast period.
Cancer Monoclonal Antibodies Market - By Type:
Cancer Monoclonal Antibodies Market - By Conjugate Cancer Therapies:
Cancer Monoclonal Antibodies Market - By Region:
Geographically, North America dominated the global cancer monoclonal antibodies market due to well-maintained healthcare infrastructure, increased government expenditure for infection control and management, and the rising commonness of life-style related diseases. The North American area is regarded to show the same growth due to the government's rise in cancer research and technology development.
Europe is anticipated to show an essential growth in the market due to an increase in autoimmune diseases' commonness, increasing the cancer population, and rising funding in research and development in the monoclonal antibodies market.
The Asia-Pacific market is regarded to increase significantly due to the increase in people's spending capacity and the growing knowledge among the patients.
KEY MARKET PLAYERS:
The highly customizable nature of the monoclonal antibodies attracts various organizations, research institutes, and multinational companies to use it as a tool to cure cancer. The major players in the Cancer Monoclonal Antibodies Market are Amgen, Genmab, GlaxoSmithKline, Bristol Myers Squibb, Roche, Eli Lilly, Immunogen, Novartis, Seattle Genetics & Spectrum Pharmaceuticals.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5.1 By Application
5.1.1 Liver
5.1.2 Breast
5.1.3 Brain
5.1.4 Blood
5.1.5 Hodgkins and Non-Hodgkins lymphoma
5.1.6 Colorectal
5.1.7 Leukaemia
5.1.8 Others
5.2 By Type
5.2.1 Murine Antibodies
5.2.2 Chimeric and Humanised Antibodies
5.2.3 Fully Humanized Antibodies
5.3 Conjugate Cancer Therapies
5.3.1 Immunoliposome
5.3.2 Radioimmunotherapy
5.3.3 ADEPT
5.3.4 Immunocytokines
5.3.5 Others
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8.1 Roche
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Amgen
8.3 Genmab
8.4 Glaxosmithkline
8.5 Bristol Meyer Squibb
8.6 Eli Lilly
8.7 Immunogen
8.8 Novartis
8.9 Seattle Genetics
8.10 Spectrum Pharmaceuticals
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
Related Reports
